Emerging pathobiological concepts include the role of aging and cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, microRNAs and mechanotransduction. Therapeutic approaches that target molecular pathways to modulate aberrant cellular phenotypes and promote tissue homeostasis in the lung must be developed. Heterogeneity in biological and clinical phenotypes of IPF warrants a personalized medicine approach to diagnosis and treatment of this lung disorder.
Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia, affecting over 100 000 persons in the US alone. A fatal lung disease with a median survival after diagnosis of only 3 years, [1] IPF affects older individuals and is slightly more prevalent among men. [2] It is characterized histologically by the presence of usual interstitial pneumonia on surgical lung biopsy and clinically by the progressive loss of lung function with resultant dyspnoea, non-productive cough and exercise limitation. There are currently no effective pharmacological therapies approved by the US FDA for IPF. Despite more recent efforts in developing antifibrotic therapeutic agents, the few drugs tested to date have not proven to be clinically beneficial. Lung transplantation is often the only option available for patients with advanced IPF, and even this has its own limitations: it is expensive, available to only a selected minority and median survival post-lung transplant is only about 5 years. There is an urgent need to identify effective antifibrotic agents for IPF. In this review, evolving concepts in IPF pathogenesis and emerging therapeutic targets for this lethal lung disease are discussed.
Current Approach to Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Until effective drug treatments become available, the management of IPF patients is, for the most part, focused on measures to improve quality of life (QOL), and preserve mobility and independence. Patients with IPF have diminished exercise capacity, increased breathlessness, depression, severe fatigue, diminished cognitive function and diminished QOL compared with the general population. Pulmonary rehabilitation has been shown to favourably impact many of these problems in the chronic obstructive pulmonary disease (COPD) population, and is recommended for patients with IPF. [1] However, large and well designed prospective studies exploring the role of pulmonary rehabilitation in IPF are lacking. Hypoxaemia is often associated with disease progression; [3] however, no conclusive studies have been performed on the effects of long-term oxygen therapy on survival. A number of small studies do suggest favourable impact of oxygen therapy on exercise capacity and QOL; [4, 5] patients with IPF and hypoxaemia are prescribed supplemental oxygen. Cough can be quite disabling in IPF and it is important to recognize that many patients will have associated problems such as upper airway cough syndrome and gastro-oesophageal reflux disease (GORD/GERD) that ought to be treated aggressively. [6] GERD is prevalent in IPF and may be potentially related to disease progression. [7] [8] [9] Most physicians now recommend aggressive treatment of GERD in IPF patients with an acid-reducing drug; however, well designed studies are needed to elucidate whether acid suppression improves IPF outcomes. [9] Sleep-disordered breathing is also common in IPF; it is often under diagnosed and negatively impacts QOL. [10] Sleep-disordered breathing can often be treated with non-invasive positive pressure ventilation, although no studies have defined the impact of this treatment in IPF. Patients with IPF have increased risk of acute coronary syndrome and deep vein thrombosis when compared with the general population. [11] Furthermore, the concomitant presence of severe coronary artery disease and IPF may be related to worse outcomes. [12] IPF patients should be managed aggressively with risk factor-modifying strategies; coronary artery disease ought to be suspected in any IPF patient presenting with worsening dyspnoea and/or deteriorating exercise capacity. Pulmonary hypertension is also common in IPF and may be associated with poor survival; [13, 14] however, further studies are needed to define the best diagnostic approaches and treatment modalities in this population. In summary, until effective drug therapies become available, IPF patients should be referred to tertiary care centres to be considered for clinical trials and lung transplantation. In addition to symptom control and QOL management, the comorbidities that may be associated with IPF also have to be considered. Most patients are appropriate candidates for pulmonary rehabilitation and oxygen therapy should be offered for those with hypoxaemia. GERD and risk factors for coronary artery disease should be treated aggressively. If sleep-disordered breathing is diagnosed, a trial of non-invasive positive pressure ventilation can be considered if no contraindications are found. Further studies are needed to define the best strategies to diagnose and treat pulmonary hypertension secondary to IPF.
What We Have Learned from IPF Clinical Trials?
Since the late 1990s, when a more uniform definition of IPF was proposed, [15] more than 3000 patients have been enrolled in clinical trials exploring novel therapies (table I) . Most of these studies allowed the use of corticosteroids in the 'placebo' arm. A small minority of these studies have met their primary endpoints, but none demonstrated survival advantage or meaningful clinical benefit in IPF. However, these studies have shed light on the natural history of IPF. A detailed analysis of the placebo arm of a large multicentre, randomized, placebo-controlled study of interferon-g-1b in patients with moderate IPF demonstrated that lung physiology had minimal Taniguchi et al. [25] Pirfenidone SpO 2 on 6MWT DFVC 275 Yes Lower decline in FVC for the group randomized to the higher dose of pirfenidone STEP-IPF [26] Sildenafil D L CO <35 6MWD 180 Yes Negative 6MWD = 6-minute walk distance; 6MWT = 6-minute walk test; A-a = alveolar-arterial gradient; Aza = azathioprine; BUILD-1 = a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis; CS = corticosteroids; D L CO = diffusion capacity for carbon monoxide; FVC = forced vital capacity; GIPF 001 = a placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis; IFIGENIA = Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual study; INSPIRE = effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis trial; NAC = N-acetylcysteine; PIPF = pirfenidone in patients with IPF; Pred = prednisone; SpO 2 = peripheral saturation of oxygen; STEP-IPF = a controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
decline during the first 12 months following randomization. [16] In fact, only later studies that followed patients beyond 72 weeks observed mean declines in forced vital capacity (FVC) around or beyond the 10% threshold considered to be associated with increased risk of mortality. [22, 24] In the same study, approximately half the deaths that occurred acutely were preceded by a period of rapid clinical deterioration that did not have an identifiable cause besides 'disease progression'. [27] Although there was an overall trend towards worsening dyspnoea and deterioration of physiological parameters just prior to death, there was enormous variability among patients and the initial FVC did not seem to predict these events. These findings emphasize the generally unpredictable course of IPF and the need for early referral to a tertiary care centre for early lung transplant evaluation.
The IFIGENIA (Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual) study, which compared the effectiveness of 1 year of therapy with the antioxidant N-acetylcysteine (NAC) in addition to combination therapy with prednisone and azathioprine, is one of only three phase III clinical trials in IPF that met its primary endpoint. [18] At the end of the study, patients on triple therapy had significantly less decline in vital capacity and diffusion capacity compared with patients who took only prednisone and azathioprine. The lack of a placebo-only control group and the significant rate of dropouts during the study have prevented the scientific community from embracing this therapy as standard of care in IPF. The National Institutes of Health (NIH)-sponsored IPF Clinical Research Network (IPFnet) is currently enrolling patients in a threearm randomized and controlled study comparing triple therapy (prednisone, azathioprine and NAC) versus NAC alone and versus placebo. This study (PANTHER-IPF [Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF]) is expected to complete enrolment in late 2011.
Kubo and collaborators conducted a prospective, randomized, open-label study of 64 patients with well characterized IPF admitted to a hospital in Japan to evaluate potential for anticoagulation to improve mortality in IPF. [19] All patients had demonstrated prior evidence of clinical deterioration and were on corticosteroids at the time of enrolment. Patients were randomized to receive either anticoagulants plus corticosteroids (n = 31) or corticosteroids alone (n = 33). The anticoagulant regimen consisted of outpatient oral warfarin (coumadin) titrated to an international normalized ratio (INR) of 2-3 and intravenous low molecular weight heparin during hospitalizations for acute exacerbations. All patients also received intravenous methylprednisolone when hospitalized with acute respiratory deterioration related to IPF. However, corticosteroids were stopped whenever patients were hospitalized with either bacterial infection or heart failure. The group overall had relatively mild physiological impairment (FVC 70% of predicted; diffusion capacity for carbon monoxide [D L CO] 60% of predicted). As 8 of 31 subjects withdrew in the anticoagulant group, the analyzed cohort constituted a group of 56 patients, 23 of whom received anticoagulants. There was a significant improvement in survival in the anticoagulant-treated group (hazard ratio 2.9; 95% CI 1.0, 8.0; p = 0.04). Furthermore, the mortality associated with the episodes of acute exacerbation was also significantly reduced in the anticoagulation-treated group (18% vs 71%; p = 0.008). [19] This clinical trial provides us with initial evidence of a possible survival benefit of anticoagulation in human IPF; however, some concerns regarding the methodology have been raised. This study enrolled patients at the time of their hospitalization and most subjects did not have advanced disease, making it more difficult to explain why survival in the control group was much lower than reported in other recent IPF clinical trials. Furthermore, an intent-to-treat analysis of the whole randomized patient cohort might have been more appropriate. The results of this study warrant confirmation with a larger, multicentre, randomized and placebo-controlled clinical trial before the use of anticoagulation can be recommended as standard of care for IPF patients. The IPFnet conducted a study (ACE-IPF [Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis]) comparing warfarin versus placebo for patients with IPF. This study was recently stopped prior to reaching targeted enrolment by recommendation of the study's Data and Safety Monitoring Board (DSMB); results of the trial should be available later this year. [28] Pirfenidone is a molecule believed to have both anti-inflammatory and antifibrotic effects. In 2005, Azuma and collaborators published a clinical trial in which 107 IPF patients were randomized to receive either pirfenidone or placebo. [17] Although this study failed to reach its primary endpoint (change in lowest oxygen saturation by pulse oximetry between baseline and 9 months during a 6-minute exercise test), the number of individuals with improved or stable vital capacity and total lung capacity was greater in the pirfenidone group than the placebo group. The study was stopped early by the DSMB because more patients in the placebo group experienced acute exacerbations of IPF. [17] These promising findings led to three subsequent large clinical trials on pirfenidone. Taniguchi and collaborators randomized 275 Japanese IPF patients to either pirfenidone 1800 mg or 1200 mg, or placebo. [25] Patients randomized to the higher dose group had significantly lower decline in vital capacity and a similarly significant difference was seen in progression-free survival, which was a secondary endpoint. [25] A major methodological concern is that the primary endpoint was changed after the trial was started; the handling of missing data may have also magnified the treatment effect of pirfenidone. In the US, two large clinical trials of pirfenidone were recently concluded. Both studies recruited patients with mild to moderate IPF and were powered with ''change in lung function over time'' as the primary endpoint. PIPF 004 [29] randomized 435 patients in a 2 : 2 : 1 model to a higher dose group, a placebo group, or a lower dose group, respectively. PIPF 006 [30] enrolled 344 patients in a 1 : 1 model to either a high-dose group or a placebo group. Although PIPF 004 did meet its primary endpoint, PIPF 006 did not. The data from these studies have been recently published [24] and were presented to the US FDA; [31] however, this agent has not been approved for treatment of IPF in the US.
Many challenges lie ahead as future clinical trials in IPF are anticipated. The scientific community and regulatory authorities ought to agree on which endpoints are meaningful. Clinical trials powered around a mortality endpoint require larger numbers of patients, longer periods for enrolment and follow-up, and carry increased cost. Other endpoints such as change in lung function over time are felt by many to be adequate surrogates for mortality, but are yet to be rigorously validated.
Risk Factors for IPF

Inhalational Exposures
IPF is a disease process that appears limited to the lungs, without clear evidence at the current time that other organs systems are involved. Thus, it seems intuitive that the injurious agent or antigen may have been transmitted to the lung via the inhaled route. Many studies have looked at the possible role of inhalational exposures and risk of developing IPF. Most of the studies are case-control studies and suggest associations rather than causality. Additionally, most of these studies were reported prior to the 2002 joint American Thoracic Society and European Respiratory Society consensus statement on the classification of idiopathic interstitial pneumonias, [1] which raises concerns regarding the reliability of the diagnoses.
Inhalational exposures to metal or wood dust and smoking have been most studied. There are several case-control studies in patients with a diagnosis of IPF that demonstrated increased odds ratios for developing IPF with exposure to metal dust, with odds ratios ranging from 1.34 to 10.97. [32] [33] [34] [35] [36] [37] Case-control studies also suggest a link between exposure to wood dust and risk of IPF. [32, 33, 35, 36] Only one of these studies was able to show a statistically significant association. [33] Another study showed a significant association between wood burning stoves in the home and IPF. [32] More recently, a study of Swedish subjects with exposure to birch dust or hardwood dust demonstrated an elevated risk of developing IPF. [38] In a US study, subjects who worked in wood buildings had increased risk of developing IPF. [37] Other occupational exposures that have been reported as possibly associated with IPF include agriculture and farming, [34, 35] livestock, [32, 35] textile dust, [33] and exposures to sand, stone and silica. [33, 35, 39, 40] There is considerable evidence that cigarette smoking is associated with a risk of developing IPF. Six case-control studies have shown a positive association between ever having smoked cigarettes and the development of IPF, [33, 35, 36, 41, 42] with a combined odds ratio of 1.58. [43] Additionally, a recent study from Mexico demonstrated that former smoking history is associated with IPF. [44] It has also been demonstrated that those IPF patients with a smoking history have decreased survival when compared with IPF patients without a smoking history. [45] Two different studies suggest that current smokers may have a better outcome compared with former smokers, which may reflect less severe disease at presentation and may represent a healthy smoker effect. [45, 46] While there is substantial epidemiological evidence that suggests associations between inhalational exposures, there are significant numbers of IPF patients with no occupational exposure history and who have no smoking history.
Gastro-Oesophageal Reflux
There is accumulating evidence of an association between GERD and IPF. Multiple epidemiological studies demonstrate a high prevalence of GERD in patients with IPF. [7, 8, 47, 48] Initially, Tobin et al. [7] demonstrated that almost all patients with IPF in their cohort had GERD, whereas only 50% in the control cohort of patients with other interstitial lung diseases had GERD. Raghu et al. [8] were able to demonstrate that 87% of IPF patients versus 68% of asthma patients studied had GERD. In both of these studies, a majority of the patients with GERD did not have the typical symptoms of GERD. [7, 8] More recently, it was demonstrated that systemic sclerosis patients with interstitial lung disease had more severe GERD and more proximal oesophageal reflux when compared with systemic sclerosis patients without interstitial lung disease. [49] It should be recognized, however, that most end-stage lung diseases are associated with a high prevalence of GERD, [50, 51] and a cause-effect relationship remains unclear.
The most compelling evidence for a role for GERD in the pathogenesis in IPF is a published case series in which four patients with IPF and GERD who were treated only for their reflux disease had stabilization or improvement in their clinical parameters. [9] Two of these patients had deterioration in pulmonary function tests and symptoms when non-compliant with anti-reflux measures that again stabilized with treatment of their reflux. [9] While this alone does not definitively link IPF and GERD, it does warrant significant consideration for GERD as a contributor to the progression of this disease, at least in a subgroup of patients.
Diabetes Mellitus
There is epidemiological evidence that supports an association between IPF and diabetes mellitus. In a case control study in Japan, a higher prevalence of diabetes was observed in IPF patients compared with the control group (odds ratio 4.06; 95% CI 1.8, 9.15). [41] In another case control study, the use of insulin was associated with the diagnosis of IPF. [48] In a more recent study from Mexico, diabetes was identified as an independent risk factor associated with IPF. [44] The potential mechanism(s) by which diabetes might contribute to the risk of developing IPF is unknown. It has been shown that there is accumulation of advanced glycation end-product (AGE)-modified proteins in alveolar macrophages in IPF patients, [52] and that blocking AGE formation can prevent bleomycin-induced pulmonary fibrosis in a mouse model. [53] However, other studies have suggested that the receptor for AGE, RAGE, might be protective from pulmonary fibrosis. IPF patients have decreased levels of RAGE in lung tissue and on type II alveolar epithelial cells, [54, 55] and RAGE-null mice have more severe pulmonary fibrosis in response to asbestos injury. [54] Further studies are warranted to elucidate the precise relationship between diabetes and increased risk of IPF.
Viral Infection
There has been growing interest in viral infections as a potential factor in the aetiology of pulmonary fibrosis, in acute exacerbations or in the progression of disease. The herpesviruses, and in particular Epstein Barr Virus (EBV), cytomegalovirus (CMV) and Kaposi's sarcoma-associated herpesvirus (KSHV), have received the most attention. The detection of herpesvirus in the lungs of IPF patients has been reported by multiple groups. In the UK it has been shown that EBV can be detected in lung tissue by immunohistochemistry and polymerase chain reaction (PCR) in 40-60% of IPF patients and in 0-4% of control patients. [56] [57] [58] In the US, Tang et al., [59] demonstrated that 97% of IPF lung specimens had evidence of EBV, CMV, KSHV or human herpesvirus 7, while only 36% of control lung specimens had evidence of one of these viruses. In this study, 57% of the IPF cases compared with only 8% of the control cases had evidence of two or more of these viruses. These authors also presented a case report of a patient with familial IPF who had evidence of EBV infection, and whose pulmonary function tests stabilized with antiviral therapy. [59] More recent studies report that EBV, CMV or KSHV was detected in the alveolar epithelium of 65% of lung specimens from IPF patients and in none of the control specimens. [60] Other studies report a failure to find evidence for herpesvirus infection in IPF patients. Hayakawa et al. [61] in Japan and Zamo et al. [62] in Italy were unable to detect herpesvirus DNA in any of the IPF and control lung specimens that they studied.
Animal models of fibrosis support the notion that herpesviruses may participate in the fibrotic process. It has been demonstrated that in T 2 -helper cell (T h 2)-biased mice, murine gammaherpesvirus-68 (a strain that is similar to EBV and KSHV in humans) infection induces progressive pulmonary fibrosis. [63] It has also been demonstrated that this same virus can exacerbate established fluoroscein isothyocyanate-induced pulmonary fibrosis in mice. [64] Further studies are required to investigate the precise role(s) that these viruses play in lungs of patients with IPF.
Emerging New Concepts in IPF Pathogenesis
Steady progress has been made in our understanding of IPF pathogenesis over the last several years. Concepts on disease pathogenesis have evolved from chronic inflammation, [65] to aberrant wound healing, [66] to current paradigms of a multifactorial and heterogeneous disease process in which cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, mechanotransduction, and the role of epigenetic mechanisms involving micro-RNAs play critical roles. In the genetically/epigenetically susceptible host, exposure to injurious agents may result in phenotypic alterations of structural cells of the lung that lead to aberrant epithelial-mesenchymal interactions and eventually to fibrosis. IPF can thus be viewed as a fundamental problem of altered tissue homeostasis and aberrant communication between cells of the lung (figure 1).
Aging and Cellular Senescence
The diagnosis of IPF is rarely made in patients <40 years of age, and both the incidence and prevalence of IPF markedly increase with advancing age. [2] Furthermore, the survival rate for IPF patients decreases with age. [46, 67] Age-related diseases may be associated with telomere dysfunction, [68] and shortening of telomeres leads to reduced capacity for stem-cell renewal and to cellular senescence. [69] Recent studies of familial and sporadic cases of IPF have been associated with telomere shortening, [70] [71] [72] suggesting that IPF may represent a degenerative disease process associated with advancing age. [73] The mechanisms of stem cell renewal, differentiation, senescence and other fates of the different cell types involved in lung fibrogenesis require further study. Few animal studies have evaluated the role of aging in fibrosis, although a study published in 1984 suggested that chronic cigarette smoke exposure in older mice, in contrast to young mice, produced morphological and functional changes suggestive of pulmonary fibrosis. [74] This suggests that age-dependent changes in pulmonary physiology, which occur even in the absence of disease, may contribute to susceptibility of the lungs to injury and/or a predisposition to fibrosis. Understanding age-dependent changes in lung physiology and the role of aging on lung injury/repair responses will provide novel insights into the pathogenesis of IPF and potential targets for therapeutic intervention.
Oxidative Stress
Oxidative stress is defined as an imbalance of the generation of reactive oxygen species (ROS) in excess of the capacity of cells/tissues to detoxify or scavenge them. Such a state of oxidative stress may alter the structure/function of cellular macromolecules that eventually leads to tissue/organ dysfunction. There is a substantial and growing body of evidence indicating that oxidative stress is not only a pathological feature of IPF, but that it likely plays an important role in the development of fibrosis in multiple organ systems. [75, 76] Lung tissue from IPF patients demonstrates 'signatures' of chronic oxidative damage. [75, [77] [78] [79] Although ROS generation may be involved in a number of normal physiological functions, overproduction of ROS may lead to oxidative stress that alters cellular phenotypes and causes tissue damage over time. [80] Oxidative stress can influence cellular phenotypes and fates, including senescence and apoptosis, which may promote a tissue microenvironment that favours fibrosis over regeneration. For example, increased oxidative stress leads to premature induction of cellular senescence, [81, 82] and fibroblasts acquire an apoptosis-resistance phenotype as a consequence of senescence. [83, 84] Senescent fibroblasts stop replicating, yet they remain metabolically active and generate higher levels of ROS. [85] Lung myofibroblasts secrete hydrogen peroxide, which may mediate fibrogenic effects in tissues by inducing epithelial cell apoptosis by a paracrine mechanism, [86] or by inducing matrix crosslinking reactions in the presence of extracellular heme peroxidases. [87] Although there is an established role for oxidative stress in mediating various cellular behaviours that influence tissue homeostasis and the outcome of repair/regeneration, age-dependent oxidative changes may provide a positive-feedback
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Endoplasmic Reticulum Stress
Endoplasmic reticulum (ER) stress of alveolar epithelial cells has been implicated in IPF. ER is a membrane-enclosed intracellular organelle that serves as the site for protein folding, processing and trafficking. Accumulation of improperly folded proteins in ER induces ER stress in the form of the adaptive response, called unfolded protein response (UPR). [88] Many proteins are involved in the UPR, including the ER chaperone Grp78 (BiP), PKR-like ER kinase (PERK), activating transcription factor (ATF)-4 and ATF-6. [88] UPR tends to limit the de novo entry of proteins into the ER and facilitate both ER protein folding and degradation, allowing protection from cell death. However, when protein misfolding is persistent or excessive, ER stress triggers cell deathtypically apoptosis through the Bcl-2 signalling pathway. [88] ER stress has been found in lung samples from both familial IPF and sporadic IPF lungs. [60, 89] Epithelial cells in IPF lungs show significant staining of BiP, EDEM (ER degradation enhancing a-mannosidase-like protein) and X-box binding protein (XBP)-1 when compared with control lung tissues, suggesting ER stress in the epithelial cells in IPF. [60] Expression of pro-SP-C (precursor protein for surfactant protein C) mutant protein in A549 cells increases BiP expression, demonstrating the presence of ER stress in these cells due to improper folding of the pro-SP-C mutant protein. [60] In another study, expression of p50ATF-6, ATF-4 and CHOP (C/EBP-homologous protein) are increased in sporadic IPF lungs when compared with control lung tissues, further supporting the view that ER stress exists in IPF lungs. [89] Importantly, the apoptotic signalling is increased in IPF in lung tissue compared with donor control lungs, [89] suggesting a connection between ER stress and lung epithelial cell death.
Although viral infection and oxidative stress have been proposed as potential mechanisms for ER stress in IPF, [60, 89] further investigation is needed to understand the exact molecular mechanisms leading to ER stress in IPF.
Cellular Plasticity
There is growing recognition for expanded plasticity of somatic cells, even those thought to be terminally differentiated. This 'plasticity' typically occurs under certain regenerative, reparative and fibrotic conditions, and involves a number of cell types, including epithelial, endothelial and mesenchymal cell types.
Epithelial-Mesenchymal Transition
Recent in vivo studies demonstrate that fibroblasts can be derived from lung epithelium during the development of lung fibrosis in animal models. Epithelial-mesenchymal transition (EpMT) is a process by which cells lose epithelial markers/ phenotype and acquire mesenchymal characteristics. [90, 91] Studies with animal models support the possibility that EpMT contributes to the accumulation of fibroblasts in lung fibrosis. [92, 93] Loss of expression of E-cadherin and surfactantprotein C, and gain of expression of a-smooth muscle actin (a-SMA) and S100A4, have been observed in fibrotic lungs induced by overexpression of transforming growth factor (TGF)-b 1 [92] or bleomycin administration. [93] In the latter study, about one-third of the S100A4-positive fibroblasts were derived from lung epithelium 2 weeks after bleomycin treatment; in contrast, few S100A4-positive cells were found in lungs in untreated mice. [93] In vitro studies indicate that TGF-b 1 in combination with epidermal growth factor (EGF) can induce EpMT; E-cadherin expression is lost, while S100A4 expression is gained in type II alveolar epithelial cells treated with both TGF-b 1 and EGF. [93] Interestingly, few epithelium-derived S100A4-positive fibroblasts in the bleomycininduced lung fibrosis model are a-SMA-positive, [93] while a subset of epithelium-derived fibroblasts in the TGF-b 1 overexpression model of lung fibrosis model are a-SMA-positive. [92] These observations suggest that different cellular phenotypes of fibroblasts and myofibroblasts coexist during the development of lung fibrosis and contribute to varying degrees in different animal models of lung fibrosis.
The role and significance of EpMT in the pathogenesis of human IPF remains unclear. Coexpression of the myofibroblast marker (a-SMA) and alveolar epithelial cell marker (pro-surfactant protein B) have been observed in cells lining alveolar spaces in human IPF lung tissues. [91] Immunohistochemical staining of IPF lung tissues also supports a role for Wnt/b-catenin signalling in IPF. [94] Laminin-5-g2 chain is associated with increased cell motility and its expression is mainly restricted to basal cell sheets located between luminal bronchiolar cells and myofibroblast clusters of fibroblast foci in human IPF lungs, suggesting that abnormal proliferation and migration of bronchiolar basal cells have a role in the remodelling process characterizing IPF. [95] The molecular mechanisms and cellular phenotypes/ fates of epithelial cells with apparent expanded cell plasticity during fibrogenesis warrant further investigation.
Endothelial-Mesenchymal Transition
In vivo data from the bleomycin-induced lung fibrosis model in mice indicate that fibroblasts in fibrotic lungs can be derived from lung capillary endothelial cells, through an endothelialmesenchymal transition (EnMT)-like process. [96] EnMT accounted for approximately 16% of lung fibroblasts isolated from bleomycin-treated mice and only about 15% of these endothelial-derived fibroblasts are a-SMA positive. [96] 
Fibroblast Heterogeneity and Plasticity
Fibroblasts likely play key regulatory functions in normal homeostasis of the adult lung, [97, 98] although their roles in extracellular matrix (ECM) synthesis and remodelling are better appreciated. Fibroblasts are perhaps best defined by their elongated spindle-like morphology, varied functions and plasticity. To date, no 'fibroblastspecific' marker has been identified. In most cases, the absence of more specific markers of other cell types and a combination of mesenchymal markers are used. Fibroblasts are known to be highly heterogeneous with respect to their cytoskeletal protein expression and architecture; the expression of myogenic or smooth muscle cell markers, such as a-SMA, identify a subset of myofibroblasts that are key effectors of tissue contraction and architectural remodelling characteristic of most chronic fibrotic disorders. [99] Fibroblast heterogeneity is also observed with respect to the expression of specific cell surface glycoproteins. [100, 101] Thy-1 is a lipid raft glycoprotein without a cytoplasmic tail. [102] Published data demonstrate that Thy-1(-) and Thy-1(+) lung fibroblasts have different roles during lung fibrosis. [101, 103] Thy-1 is involved in the regulation of myofibroblast differentiation and survival, and the latent TGF-b 1 activation. [101, 103] Importantly, Thy-1 deficiency promotes lung fibrosis in the bleomycin-induced lung fibrosis model in mice, suggesting that Thy-1 expression may limit fibrotic responses to tissue injury.
[100]
MicroRNAs in Matrix Remodelling and Fibrosis
MicroRNAs (miRNAs) are 21-22 nucleotide non-coding small RNAs. [104] The expression of miRNAs is often modulated by transcriptional factors in response to cellular stimuli. The primary transcripts of miRNAs (pri-miRs) are processed by the nuclear RNaseIII Drosha to form 70-80 nucleotide precursor miRNAs (pre-miRs). Pre-miRs are then exported to the cytoplasm, where they are processed by Dicer into mature miRNAs. Mature miRNAs, together with Dicer and Argonaute proteins, form the miRNAinduced silencing complex (miRISC). Guided by miRNA through base pairing, the miRNA complex binds to the 3 0 UTR (untranslated regions) of target genes and thereby represses translation of target genes and/or induces degradation of target gene messenger RNA (mRNA). [104] A number of recent studies have demonstrated that miRNAs play an important role in maintaining the homeostasis of the ECM. Aberrant expression of miRNAs has been linked to fibrotic diseases in various organs. [105] [106] [107] [108] [109] In the heart, miR-133 expression is reduced during nicotineinduced atrial fibrosis, and exogenous miR-133 expression in cultured atrial fibroblasts decreases levels of TGF-b 1 and TGF-bRII, and production of collagen. [110] Another study showed that both miR-133 and miR-30 regulate the expression of connective tissue growth factor (CTGF). [111] In this study, down-regulation of miR-133 and miR-30 increases the CTGF expression in cultured cardiomyocytes and fibroblasts; furthermore, overexpression of miR-133 or miR-30c decreased CTGF levels, which was accompanied by decreased production of collagens. [111] miR-133 and miR-30 directly target CTGF through conserved binding sites within 3 0 UTR of CTGF mRNA. [111] miR-29 family members are down-regulated in the region of the heart adjacent to myocardial infarct; down-regulation of miR-29 induces the expression of collagens, whereas overexpression of miR-29 in fibroblasts reduces collagen expression. [105] Recent studies by Cushing et al. [112] demonstrate that mir-29 is down-regulated in lungs of mice during fibrotic remodelling following bleomycin injury. In this study, miR-29 was found to be suppressed by TGF-b 1 in lung fibroblasts and many of the fibrosis-associated genes upregulated by TGF-b 1 were derepressed by miR-29 knockdown. miR-29 also appears to regulate other fibrosis-associated genes, independent of TGF-b 1 , [112] suggesting that strategies to induce expression of miR-29 in fibrotic lung fibroblasts may be effective. miR-21 is one of the most studied miRNAs and has been shown to be involved in carcinogenesis, inflammation and cardiovascular diseases. [113] [114] [115] miR-21 can activate the extracellular signal-regulated kinase (ERK) through targeting the sprouty homologue 1 (Spry1) in cardiac fibroblasts, and thereby contribute to cardiomyocyte hypertrophy and cardiac fibrosis. [106] miR-21 also regulates the expression of metalloproteinase (MMP)-2 in cardiac fibroblasts, [116] representing another mechanism by which miR-21 regulates cardiac remodelling. miR-216a and miR-217 regulate Akt activation through down-regulation of phosphatase and tensin homologue, an inhibitor of Akt activation. [117] Overexpression of miR-17 decreases cell adhesion, migration and proliferation, and overexpressing miR-17 directly downregulates fibronectin and induces overall growth retardation in transgenic mice. [118] Recent evidence also supports the notion that miRNAs can regulate cellular plasticity. miR-145 expression affects fibroblast differentiation into a smooth muscle cell phenotype. Inhibition of miR-145 with antisense oligonucleotide blocks a-SMA expression, [119] suggesting that miRNAs may regulate (myo)fibroblast plasticity. However, it is currently unknown if miR-145 is expressed in the lungs or whether its expression is altered in lung fibrosis. Kaminski and colleagues first reported dysregulation of miRNA expression in the lungs of IPF patients. [107] They found a number of miRNAs up-regulated, while others were down-regulated in IPF lungs. [107] One of the down-regulated miRNAs, let-7d, regulates EpMT in alveolar epithelial cells by targeting a transcriptional factor, HMGA2. Let-7d expression is down-regulated by TGF-b 1 and participates in TGF-b 1 -induced EpMT. More importantly, HMGA2 (high-mobility group AThook 2) expression is remarkably decreased in IPF lungs and inversely correlates with the levels of mesenchymal cell markers. [107] These data argue strongly for a role of miRNAs in the pathogenesis of IPF. miR-155 expression was found to be significantly increased in the lungs of mice with bleomycin-induced lung fibrosis. miR-155 targets the angiotensin II type 1 receptor and keratinocyte growth factor (KGF), suggesting that miR-155 may participate in the pathogenesis of lung fibrosis. [120, 121] miR-21 expression is markedly increased in the lungs of mice with bleomycininduced pulmonary fibrosis and in the lungs of IPF patients. [108] The enhanced expression of miR-21 is primarily localized to lung fibroblasts, and TGF-b 1 was found to up-regulate miR-21 expression in human lung fibroblasts. [108] Overexpression of miR-21 promotes, whereas downregulation of miR-21 diminishes, TGF-b 1 -induced expression of ECM proteins. These data suggest that miR-21 regulates the profibrotic effects of TGF-b 1 signalling, at least in part, by targeting the inhibitory Smad protein, Smad7. [108] This supports the possibility that miR-21 acts in a feed-forward loop to amplify TGF-b 1 effects and promote lung fibrosis.
miR-200 family members inhibit epithelialmesenchymal transition and migration in mammary epithelial cancer cells by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. The level of miR-200 family is decreased during EpMT in mammary epithelial cancer cells in response to TGF-b 1 . [122] [123] [124] However, roles for miR-200 family members specifically in pulmonary fibrosis have not been demonstrated.
Mechanotransduction
The biophysical properties of the ECM may regulate cellular plasticity and fate via integrin signalling [125] or growth factor activation. [126] Excessive TGF-b 1 production/activation is central to the pathogenesis of IPF. TGF-b 1 is initially secreted as an inactive latent complex (termed the small latent TGF-b, SLC), which consists of an N-terminal latency-associated peptide (LAP) and a C-terminal active TGF-b domain. The association of LAP prevents active TGF-b from binding to its receptors for biological functions. [127] [128] [129] Most cells secrete TGF-b as a large latent complex in which the SLC binds to a second protein, latent TGF-b binding protein (LTBP). [130, 131] The binding of LTBPs (LTBPs-1, 3 and 4) facilitates TGF-b secretion, deposition into the ECM and latent complex activation. [132, 133] Both in vivo and in vitro studies have demonstrated that latent TGF-b 1 activation, a process that results in the release/exposure of active TGF-b 1 from the latent complex, is a crucial step in lung fibrosis. [134] [135] [136] Active TGF-b 1 promotes epithelial cell apoptosis, stimulates fibroblast proliferation, migration and differentiation into myofibroblasts, induces synthesis of ECM proteins and inhibits their degradation, and prevents myofibroblast apoptosis. [137] [138] [139] [140] Recent studies demonstrate that mechanical forces induce latent TGF-b 1 activation. [126, 141, 142] Lung myofibroblasts acquire contractile activities by formation of a-SMA-containing stress fibres. Myosin-produced contractile forces transmit to the ECM through transmembrane integrins, primarily integrin a v b 5 . [126] The latent TGF-b 1 complex binds to integrin-b 5 subunits with an Arg-GlyAsp (RGD) motif and matrix fibronectin or fibrilin-1 with LTBP-1. [143] [144] [145] Myofibroblast stress fibre-generated forces transmit to the latent TGFb 1 complex, causing a conformational change that releases or exposes the active TGF-b 1 portion. Since active TGF-b 1 is sufficient for myofibroblast differentiation, it is plausible that myofibroblast contraction-induced latent TGF-b 1 activation may be a driving force for persistence of myofibroblasts in IPF. It has been demonstrated that integrin a v b 6 -mediated epithelial TGF-b 1 activation is critical for bleomycin-induced lung fibrogenesis. [134] Mechanisms underlying a v b 6 -mediated TGF-b 1 activation are not fully understood. Evidence that a v b 6 -mediated latent TGF-b 1 activation is proteinase-independent, [134] is augmented by Rho/Rho-kinase activation [146] and that truncated b 6 lacking cytoplasmic domains prevents latent TGF-b 1 activation, [147] suggests that cytoskeleton-dependent traction forces might mediate a v b 6 -mediated latent TGF-b 1 activation.
The activation of ECM-bound latent TGF-b 1 activation by fibrogenic lung fibroblasts lacking the glycosylphosphatidyl-inositol (GPI)-linked cell surface glycoprotein Thy-1 requires LTBP-4. [103, 148] LTBP-4 presents latent TGF-b 1 in a soluble form, which facilitates MMP-mediated latent TGF-b 1 activation. [101] Thus, LTBP-4 may be required for latent TGF-b 1 activation by fibrogenic lung fibroblasts and lung fibroblast-to-myofibroblast differentiation, whereas myofibroblast contractioninduced latent TGF-b 1 activation may be more important in maintaining the myofibroblastic phenotype in persistent lung fibrosis.
Emerging Approaches to IPF Treatment
Protein Kinase Inhibitors
Focal adhesion kinase (FAK) and Src kinases are non-receptor tyrosine kinases. FAK plays an important role in mediating cell migration, proliferation and differentiation. [149] FAK activation is necessary for fibroblast-to-myofibroblast differentiation. [150, 151] Inhibition of FAK activation, by expression of autophosphorylation-deficient mutant, [150] a negative FAK regulator (FAKrelated non-kinase, FRNK), [151, 152] or by using pharmacological inhibitors, [150, 152] abrogates TGFb 1 -induced myofibroblast differentiation in human lung fibroblasts. FAK contributes to the prosurvival signalling and promotes an anoikisresistant phenotype of myofibroblasts in response to TGF-b 1 . [153] Recent observations indicate that FAK activity is increased in lung fibroblasts derived from IPF patients, while the expression of the endogenous FAK inhibitor, FRNK, is decreased in the same IPF lung fibroblasts. [152] FAK inhibitors have been studied in tumour cells and in animal tumour models with promising results on inhibition of tumour growth, progression and metastasis; this has led to ongoing clinical trials of FAK inhibitors in multiple cancers. [149] FAK and Src can reciprocally activate each other, [154] and Src kinases appear to regulate fibroblast activation in systemic sclerosis. [155] Given the findings that Src/FAK play an essential role in myofibroblast differentiation and survival, inhibition of Src and/or FAK signalling through either pharmacological inhibitors or upregulation of FRNK may prove to be an effective therapeutic strategy for the treatment of IPF. [156] Mitogen activated protein kinases (MAPKs) are involved in TGF-b-induced signalling and responses. [151, 157, 158] TGF-b 1 can activate the MAPK signalling cascade, and activated MAPK signalling is required for TGF-b 1 -induced protein expression, including collagen and other ECM proteins. [151, 157, 158] The three classical MAPKsextracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinases/stress-activated protein kinase (JNK/SAPK) -are involved in the regulation of Smad proteins and TGF-b-induced myofibroblast differentiation. [151, 159, 160] Inhibition of ERK and p38 activation by FRNK overexpression inhibits myofibroblast differentiation induced by TGF-b 1 . [151] Pharmacological inhibitors of JNK and p38 MAPKs have been used to inhibit collagen production in cells in vitro and inhibit the development of fibrosis in animal models. p38 MAPK inhibitors are being evaluated in phase II clinical studies in several diseases, including rheumatoid arthritis, psoriasis and COPD. The potential utility and safety of MAPK inhibitors in fibrotic disorders requires further study.
MicroRNAs
Due to their small size, miRNAs can be modified for in vivo administration. Blocking miRNA activities in vivo has been achieved in a number of studies using oligonucleotide probes with different chemical modifications to enhance their stability, such as locked nucleotide acid (LNA) and 2 0 -OMe sugar modifications. [106, 161] Oligonucleotide probes have sequences complementary to specific miRNAs and irreversibly bind to target miRNAs. Expressing a mature miRNA in vivo has been more difficult due to the instability of single-stranded RNAs; employing viral vectors and direct intravenous administration of miRNA mimetics have been reported. [162, 163] Given the important roles of miRNAs in the regulation of ECM homeostasis and organ fibrosis, including IPF, they are appealing targets for the design of novel therapeutics. In recent studies of lung fibrosis, LNA-modified anti-miR-21 probes were employed to block miR-21 activity in a murine model of injury repair. When given intratracheally, the anti-miR-21 probes effectively sequestered mature miR-21 and significantly diminished bleomycin-induced pulmonary fibrosis in mice. [108] This is the first example of targeting miRNAs to experimentally treat pulmonary fibrosis. In another study, Kaminski and colleagues showed that down-regulating let-7d by antagomirs induces EpMT in mouse lungs. [107] Given that let-7d is down-regulated in the lungs of IPF patients, augmentation of let-7d in the lung may prove effective. In spite of the early successes of miRNA modulation in treating a variety of diseases, including pulmonary fibrosis, cell type-and organ-specific targeting has not been achieved and unexpected side effects may occur.
Targeting Myofibroblast Contractility
Myofibroblasts are key effector cells for the connective tissue remodelling characteristic of IPF. Persistent myofibroblast differentiation/survival may play a central role in the pathogenesis of IPF. Targeting the myofibroblast contractile phenotype represents a promising new strategy for developing therapeutic interventions for IPF.
Myofibroblasts are specialized contractile cells that produce contractile forces with a-SMAcontaining microfilament bundles or stress fibres. The finding that myofibroblast-produced contractile forces are transmitted to fibrogenic signals by induction of latent TGF-b 1 activation suggests that blocking myofibroblast force generation or targeting the mechanotransduction machinery associated with latent TGF-b 1 activation represents a potential antifibrotic strategy. Myofibroblast force generation is mainly regulated by myosin light chain (MLC) phosphorylation, a process that is controlled by the opposing activities of MLC phosphatase and MLC kinase. Regulation of MLC phosphatase activity has been proposed as the primary mechanism for sustained myofibroblast contraction. [164] The Rho/ Rho kinase (ROCK) pathway plays an important role in regulation of myofibroblast force formation. Activated ROCK inactivates myosin phosphatase by phosphorylating the myosin-binding subunit of this enzyme complex, which results in increased MLC phosphorylation and myofibroblast contraction. Conversely, inhibition of ROCK promotes myosin phosphatase activity, which decreases MLC phosphorylation and inhibits myofibroblast contraction. [165, 166] ROCK inhibitors are a newly developed class of drugs with potential therapeutic benefits in treating numerous pathological processes, including tissue fibrosis. [167] [168] [169] [170] The ROCK inhibitor Y-27632 has been shown to inhibit tubulointerstitial kidney fibrosis and liver fibrosis in rodent models. [171, 172] Another ROCK inhibitor, fasudil, attenuates hypertensive glomerulosclerosis in Dahl salt-sensitive rats. [173] SLx-2119, a newly developed ROCK inhibitor, reduces fibroblast stress fibre formation in radiation-induced intestinal fibrosis. [174] Inhibition of myofibroblast contractile forces by ROCK inhibitors may represent an effective mechanism-based therapeutic intervention for developing drugs for the treatment of IPF. In addition, it has been shown that a-SMA expression and its incorporation into the stress fibres increase myofibroblast contractile forces. [175] Delivery of AcEEED, a sequence specific to N-terminal a-SMA (SMA-FP), significantly reduces myofibroblast contractility. [176] Transmembrane integrins are an important mechanotransducer on the cell surface. Integrin a v b 5 is the primary integrin responsible for mechano-induced latent TGF-b 1 activation by lung myofibroblasts. [126] The small latent TGF-b 1 complex binds to the b 5 -subunit with a RGD motif in its LAP portion. Blocking the interactions between b 5 and LAP with either synthetic RGD peptides or neutralizing antibodies against a v b 5 abolishes mechano-induced latent TGF-b 1 activation. [126] Thy-1 interacts with integrin a v b 5 with an RGD-like motif, RLD. [103] Lung fibroblasts null for Thy-1 or expressing non integrin-binding Thy-1 (RLD mutated to RLE) respond to endothelin-1-induced contraction with increased latent TGF-b 1 activation, whereas lung fibroblasts expressing wild-type Thy-1 do not, [103] suggesting that Thy-1 interruption of integrin-LAP interactions blocks mechano-induced latent TGF-b 1 activation. Together, these studies support the concept that targeting the mechano-transduction machinery involved in latent TGF-b 1 activation represents another approach to inhibiting persistent myofibroblast contraction/activation in IPF.
Modulation of Oxidative Stress
The established link between IPF and increased oxidant burden provides strong rationale for the investigation of antioxidants as a therapeutic strategy. [75] A deficiency in the tripeptide antioxidant, glutathione (GSH), in the lung epithelial lining fluid has been thought to play a role in the pathogenesis and progression of IPF. [177, 178] Therefore, it is reasonable to envision that therapeutic interventions aimed at increasing GSH levels may be a viable strategy for inhibiting the progression of IPF. NAC exerts its function as an antioxidant via its main metabolite, cysteine, a precursor of GSH biosynthesis. The antifibrotic effects of NAC have been documented in animal models of lung fibrosis. Furthermore, a study of high-dose NAC therapy in patients with IPF demonstrated clinical efficacy, and is one of the few phase III trials to meet the predetermined primary endpoint of the study. [18] In this clinical trial (IFIGENIA), patients were treated with NAC, an antioxidant, in addition to the standard treatment regimen (prednisone, azathioprine). Patients demonstrated preservation of FVC and D L CO in the NAC-treated group. Despite limitations of this clinical trial, the development of therapeutic strategies targeting oxidative stress pathways remains promising. An ongoing NIH IPFnet-sponsored clinical study (PANTHER) will evaluate the effectiveness of NAC alone or in combination with prednisone and azathioprine versus placebo control. [179] A member of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) family of enzymes, NOX4, has been recently implicated in lung fibrogenesis. [180] In this study, NOX4-dependent generation of ROS (specifically, H 2 O 2 ) was found to be required for TGF-b 1 -induced myofibroblast differentiation, ECM production and contractility of lung myofibroblasts. NOX4 is up-regulated in lungs of human subjects with IPF, and genetic or pharmacological targeting of NOX4 attenuated lung fibrogenesis in two different murine models of lung injury. [180] Therapeutic strategies that more directly target the source(s) of ROS generation, including pharmacological inhibitors of NOX4, may prove to be more specific and effective compared with antioxidant interventions for IPF.
Conclusion: Personalized Medicine for IPF
Many of the evolving treatments that we have discussed are targeted towards halting the fibrotic process. Even if an effective therapeutic is identified, patients must be identified early in the disease process and the drug must be 'personalized' for the individual, ideally with reliable biomarkers that identify at-risk patients and targeted use of available therapeutic agents. A major problem with IPF is that diagnosis is often delayed until the lungs are severely scarred and the resulting loss of lung volume reserve and gasexchange capacity eventually manifests in clinical symptoms. Another major problem is the heterogeneity of the patient population. We have already discussed that there are likely multiple possible environmental risk factors that predispose a patient to pulmonary fibrosis; since not all patients with these exposures develop pulmonary fibrosis, there must be individual genetic predispositions that confer susceptibility to individual patients. To make a significant impact in IPF, focus must be on early diagnosis, risk factor modification and the identification of distinct subpopulations most likely to benefit from specific therapeutic interventions.
There has been much attention given to the idea of personalized medicine. The guiding principle behind personalized medicine is that an individual's genetic makeup can provide the information necessary to make more informed decisions on disease treatments by minimizing toxicities to drugs and choosing drugs that will target patient-specific molecular phenotypes of a disease. [181] There are two main goals of personalized medicine: (i) to use genomics to determine susceptibility of disease for prevention and early treatment; and (ii) to diagnose and treat diseases by their molecular profiles, and not just the usual signs and symptoms. [181] IPF is an ideal disease for the application of personalized medicine, since this approach is likely to work best in disorders that are caused by a combination of genetic and environmental factors, and in diseases that tend to be chronic.
In order for personalized medicine to be effective in diagnosis and/or treatment of IPF, we must understand the underlying genetic alterations and molecular pathways that lead to this disease; therapeutic agents targeting these pathways must be discovered and developed into the clinic. Several recent studies have suggested multiple biomarkers that might be useful in distinguishing IPF patients from those with other lung diseases and healthy controls such as the major histocompatibility complex class I chain-related gene A (MICA) polymorphisms, [182] MMP-1, [183, 184] MMP-7, [184] oxidative stress [185] and telomere shortening, [71, 72] among others. However, none of these biomarkers have been prospectively studied to determine if they predict early disease. Other studies have demonstrated that some biomarkers may be useful to identify patients who have a more rapid progression and earlier mortality. Serum surfactant protein A (SpA), [186] serum chemokine (C-C motif) ligand (CCL)18 levels, [187] and TGFb 1 polymorphisms [188] have all been suggested as potential biomarkers of disease progression. Clinical trials could be focused on those patients predicted to rapidly progress and those more likely to gain benefit from a particular therapeutic agent. While personalized medicine holds great promise in the future management of IPF, efforts must continue to gain better understanding of disease pathogenesis, to identify reliable biomarkers of disease activity/progression, and to develop novel antifibrotic agents that can be tested in well designed, randomized and 'personalized' clinical trials.
